Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 16/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | CTRC | Q99895 | 2/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23894834 | 0.90 | ACE (0.51) | CMA1ACE | |
| SCHEMBL9699161 | 0.90 | CMA1 (0.65) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL9699165 | 0.90 | CMA1 (0.65) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL23894836 | 0.88 | CMA1 (0.54) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL23894838 | 0.87 | ACE (0.45) | CMA1ACEPREP | |
| SCHEMBL9699092 | 0.84 | CMA1 (0.67) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL9699084 | 0.84 | CMA1 (0.67) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL9700520 | 0.83 | CMA1 (0.58) | CMA1ACECTRCPREP | |
| SCHEMBL9700519 | 0.83 | CMA1 (0.58) | CMA1ACECTRCPREP | |
| SCHEMBL23894833 | 0.83 | BCL2 (0.54) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357319-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-11-09 | — | — | US | disclosed |
| US-20230357319-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-11-09 | — | — | US | disclosed |
| US-11578101-B2 | Proteasome inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210309695-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-10-07 | — | — | US | disclosed |
| WO-2020033437-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578101-B2 | Proteasome inhibitors | PSMG3, PSME1, PSMB1 | CMA1 713/4885F2 4853/4885PRSS1 446/4885 |
| US-20210309695-A1 | PROTEASOME INHIBITORS | PSMG3, PSME1, PSMB1 | CMA1 713/4885F2 4853/4885PRSS1 446/4885 |
| US-20230357319-A1 | PROTEASOME INHIBITORS | PSMG3, PSME1, PSMB1 | CMA1 713/4885F2 4853/4885PRSS1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.